421 related articles for article (PubMed ID: 23872476)
1. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP.
Maugeais C; Perez A; von der Mark E; Magg C; Pflieger P; Niesor EJ
Biochim Biophys Acta; 2013 Nov; 1831(11):1644-50. PubMed ID: 23872476
[TBL] [Abstract][Full Text] [Related]
2. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
[TBL] [Abstract][Full Text] [Related]
3. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
4. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP.
Lauer ME; Graff-Meyer A; Rufer AC; Maugeais C; von der Mark E; Matile H; D'Arcy B; Magg C; Ringler P; Müller SA; Scherer S; Dernick G; Thoma R; Hennig M; Niesor EJ; Stahlberg H
J Struct Biol; 2016 May; 194(2):191-8. PubMed ID: 26876146
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
7. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
[TBL] [Abstract][Full Text] [Related]
8. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
[TBL] [Abstract][Full Text] [Related]
9. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
10. Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation.
Yamashita S; Matsuzawa Y
Curr Opin Lipidol; 2016 Oct; 27(5):459-72. PubMed ID: 27454452
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia.
Tall A; Sammett D; Granot E
J Clin Invest; 1986 Apr; 77(4):1163-72. PubMed ID: 3958185
[TBL] [Abstract][Full Text] [Related]
12. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice.
Rocco DD; Okuda LS; Pinto RS; Ferreira FD; Kubo SK; Nakandakare ER; Quintão EC; Catanozi S; Passarelli M
Lipids; 2011 Jul; 46(7):617-25. PubMed ID: 21479674
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester diffusion, location and self-association constraints determine CETP activity with discoidal HDL: excimer probe study.
Dergunov AD; Shabrova EV; Dobretsov GE
Arch Biochem Biophys; 2014 Dec; 564():211-8. PubMed ID: 25449063
[TBL] [Abstract][Full Text] [Related]
14. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
16. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
19. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nurmohamed NS; Ditmarsch M; Kastelein JJP
Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
